Selective ischemic-hemisphere targeting Ginkgolide B liposomes with improved solubility and therapeutic efficacy for cerebral ischemia-reperfusion injury

Yang, Li; Zhang, Miaomiao; Li, Shiyi; Zhang, Longlong; Kim, Jisu; Qiu, Qiujun; Lu, Wenyue; Wang, Jianxin

doi:10.1016/j.ajps.2023.100783

Cited by 11 publications

(15 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Li et al coupled ginkgolide B with the unsaturated fatty acid docosahexaenoic acid and encapsulated it in liposomes for the targeted treatment of CIRI. [352] Nevertheless, several factors can impede drug entry into the brain via CMT. First, CMT is concentration-limited, and molecules are usually transported in the direction of the concentration gradient.…”

Section: Carrier-mediated Transportmentioning

confidence: 99%

“…Gao et al engineered a biomimetic core-shell nanostructure for encapsulating CUR within human serum albumin nanoparticles, which were then disguised with erythrocyte membranes. They attached T807 (a positron emission tomography imaging agent with neuronal cell-binding specificity) [401,402] and triphenylphosphine (a mitochondria-targeting ligand) [403] to the Ginkgolide B [ 352] ( Puerarin [ 425] Cerebral ischemic stroke…”

Section: Alzheimer's Diseasementioning

confidence: 99%

See 1 more Smart Citation

Progress in the Treatment of Central Nervous System Diseases Based on Nanosized Traditional Chinese Medicine

Li,

Long,

Ding

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Traditional Chinese Medicine (TCM) is widely used in clinical practice to treat diseases related to central nervous system (CNS) damage. However, the blood‐brain barrier (BBB) constitutes a significant impediment to the effective delivery of TCM, thus substantially diminishing its efficacy. Advances in nanotechnology and its applications in TCM (also known as nano‐TCM) can deliver active ingredients or components of TCM across the BBB to the targeted brain region. This review provides an overview of the physiological and pathological mechanisms of the BBB and systematically classifies the common TCM used to treat CNS diseases and types of nanocarriers that effectively deliver TCM to the brain. Additionally, drug delivery strategies for nano‐TCMs that utilize in vivo physiological properties or in vitro devices to bypass or cross the BBB are discussed. This review further focuses on the application of nano‐TCMs in the treatment of various CNS diseases. Finally, this article anticipates a design strategy for nano‐TCMs with higher delivery efficiency and probes their application potential in treating a wider range of CNS diseases.

show abstract

Section: Carrier-mediated Transportmentioning

confidence: 99%

Section: Alzheimer's Diseasementioning

confidence: 99%

Progress in the Treatment of Central Nervous System Diseases Based on Nanosized Traditional Chinese Medicine

Li,

Long,

Ding

et al. 2024

Advanced Science

View full text Add to dashboard Cite

show abstract

“…This results in locally controlled drug release in ischemic areas through ROS-responsive or hypoxia-sensitive groups (Figure 6a) (Y. Li, Zhang, et al, 2023;Quan et al, 2023).…”

Section: Application Of Liposomes In Brain Repairmentioning

confidence: 99%

“…(a-c) Ligand-modified liposomes play a crucial role in targeted delivery for GBM (Y. Li, Zhang, et al, 2023;Mellinger et al, 2023;K. Wang, Zhou, et al, 2023).…”

Section: Application Of Liposomes In Brain Repairmentioning

confidence: 99%

“…Liposomes for brain repair. (a–c) Ligand‐modified liposomes play a crucial role in targeted delivery for GBM (Y. Li, Zhang, et al, 2023; Mellinger et al, 2023; K. Wang, Zhou, et al, 2023). Reproduced with permission from Y. Li, Zhang, et al (2023), Copyright 2023, the Author(s); Mellinger et al (2023), Copyright 2023, the Author(s); K. Wang, Zhou, et al (2023), Copyright 2023, the Author(s).…”

Section: Delivery Of Liposomes To Target Organsmentioning

confidence: 99%

See 1 more Smart Citation

The application strategy of liposomes in organ targeting therapy

Xun,

Li,

Xue

2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Liposomes—microscopic phospholipid bubbles with bilayered membrane structure—have been a focal point in drug delivery research for the past 30 years. Current liposomes possess a blend of biocompatibility, drug loading efficiency, prolonged circulation and targeted delivery. Tailored liposomes, varying in size, charge, lipid composition, and ratio, have been developed to address diseases in specific organs, thereby enhancing drug circulation, accumulation at lesion sites, intracellular delivery, and treatment efficacy for various organ‐specific diseases. For further successful development of this field, this review summarized liposomal strategies for targeting different organs in series of major human diseases, including widely studied cardiovascular diseases, liver and spleen immune diseases, chronic or acute kidney injury, neurodegenerative diseases, and organ‐specific tumors. It highlights recent advances of liposome‐mediated therapeutic agent delivery for disease intervention and organ rehabilitation, offering practical guidelines for designing organ‐targeted liposomes.This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology‐Inspired Nanomaterials > Lipid‐Based Structures

show abstract

Blood–Brain Barrier‐Penetrating and Lesion‐Targeting Nanoplatforms Inspired by the Pathophysiological Features for Synergistic Ischemic Stroke Therapy

Tang,

Yin,

Liu

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Ischemic stroke is a dreadful vascular disorder that poses enormous threats to the public health. Due to its complicated pathophysiological features, current treatment options after ischemic stroke attack remains unsatisfactory. Insufficient drug delivery to ischemic lesions impeded by the blood‐brain barrier (BBB) largely limits the therapeutic efficacy of most anti‐stroke agents. Herein, inspired by the rapid BBB penetrability of 4T1 tumor cells upon their brain metastasis and natural roles of platelet in targeting injured vasculatures, a bio‐derived nanojacket was developed by fusing 4T1 tumor cell membrane with platelet membrane, which further clothed on the surface of paeonol and polymetformin‐loaded liposome to obtain biomimetic nanoplatforms (PP@PCL) for ischemic stroke treatment. The designed PP@PCL could remarkably alleviate ischemia‐reperfusion injury by efficiently targeting ischemic lesion, preventing neuroinflammation, scavenging excess reactive oxygen species (ROS), reprogramming microglia phenotypes, and promoting angiogenesis due to the synergistic therapeutic mechanisms that anchor the pathophysiological characteristics of ischemic stroke. As a result, PP@PCL exerted desirable therapeutic efficacy in injured PC12 neuronal cells and rat model of ischemic stroke, which significantly attenuated neuronal apoptosis, reduced infarct volume, and recovered neurological functions, bringing new insights into exploiting promising treatment strategies for cerebral ischemic stroke management.This article is protected by copyright. All rights reserved

show abstract

Selective ischemic-hemisphere targeting Ginkgolide B liposomes with improved solubility and therapeutic efficacy for cerebral ischemia-reperfusion injury

Cited by 11 publications

References 80 publications

Progress in the Treatment of Central Nervous System Diseases Based on Nanosized Traditional Chinese Medicine

Progress in the Treatment of Central Nervous System Diseases Based on Nanosized Traditional Chinese Medicine

The application strategy of liposomes in organ targeting therapy

Blood–Brain Barrier‐Penetrating and Lesion‐Targeting Nanoplatforms Inspired by the Pathophysiological Features for Synergistic Ischemic Stroke Therapy

Contact Info

Product

Resources

About